Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Helbekkmo, Nina
ASTEROID, NCT03446547: Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)	Recruiting	2	106	Europe	Durvalumab, Medi4736	Vastra Gotaland Region, AstraZeneca	NSCLC, Stage I	07/24	07/24
DART, NCT04392505 / 2019-002537-11: Durvalumab(MEDI4736) After chemoRadioTherapy() for NSCLC-a Translational and Biomarker Study	Active, not recruiting	2	100	Europe	Durvalumab Injection, Imfinzi	Oslo University Hospital, AstraZeneca	Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III, NSCLC, NSCLC, Stage III	05/25	05/33